# CJC-1295 / Ipamorelin Blend

> This blend pairs CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH), with ipamorelin, a selective ghrelin-receptor agonist. It is the most widely referenced growth-hormone secretagogue combination, based on the idea that stimulating two distinct receptor pathways produces a larger GH pulse than either peptide alone. Both components have individually been studied for their effects on GH release in humans, though the fixed combination itself has not been evaluated as a distinct product in controlled trials. It is commonly discussed in the context of recovery, body composition, and general anti-aging research. It is not approved for human medical use outside controlled research settings.

- URL: https://www.lifeconverted.com/peptides/cjc1295-ipamorelin-blend
- Also known as: CJC/Ipa Blend, GH Blend
- Primary category: GH Blends
- Effectiveness rank: #999 in Growth Hormone Peptides; #999 in GH Releasing Hormones; #1 in GH Blends
- Evidence level: Well studied
- Route: Subcutaneous (Injected subcutaneously into the abdomen, commonly at bedtime or in a fasted state to align with natural growth-hormone pulsatility; both peptides are typically drawn into the same syringe.)
- Dose range: 200-500 mcg
- Dose tiers: low 200 mcg; moderate 300 mcg; high 500 mcg
- Half-life: CJC-1295 without DAC is reported at roughly 30 minutes, while the DAC-modified form extends to several days; ipamorelin is reported at approximately 2 hours. Overall blend duration depends heavily on which CJC-1295 form is used.
- Timing: ~30 min before bed, empty stomach
- Cycle: 8-12 weeks on, 4 weeks off (Cycling is commonly cited to reduce theoretical downregulation of pituitary responsiveness, particularly with DAC-containing formulations.)
- Storage: Refrigerate after reconstitution (2-8°C); most compounded blends are described as stable for 3-4 weeks.

## Mechanism of action

CJC-1295 binds GHRH receptors on pituitary somatotrophs, increasing synthesis and pulsatile release of growth hormone. Ipamorelin independently activates the ghrelin receptor (GHS-R1a), amplifying pulsatile GH release with a comparatively selective profile that is reported to produce less concurrent cortisol and prolactin stimulation than older secretagogues. Because the two act on separate receptor pathways, the combination is described in the literature as producing a synergistic GH pulse larger than either peptide individually.

## Reported benefits

- Amplifies growth-hormone pulse compared with either component alone
- Associated with improved recovery
- Supports lean body composition in research contexts
- Reported to improve sleep quality
- Widely used as a general anti-aging research pairing

## Reported side effects

- Water retention
- Injection site reaction
- Tingling or flushing
- Mild increase in hunger
- Headache

## Common protocols

- GH Optimization
- Muscle Growth
- Anti-Aging
- Sleep & Recovery

## Stacking notes

Considered the reference-standard GH secretagogue pairing; often used as the GH-axis backbone alongside recovery-focused peptides such as BPC-157.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer